Aidoc – the leading provider of AI solutions for radiologists – announced that the FDA has allowed the use of their cleared AI algorithms intended for adjunctive use in the detection of findings associated with COVID-19.

Diffbot Announces Access Through Microsoft Excel and Google Sheets to Supercharge Data Collection Needs

The product detects and prioritizes incidental CT findings associated with COVID-19 (e.g. GGO – a non-specific imaging finding associated with COVID-19 infection) in any CT study that contains the lung or part of the lung – for example chest, abdomen or cervical spine. Prioritization of these incidental findings may help manage the adverse effects of COVID-19 by providing adjunctive information that can promote further patient evaluation.

“In our experience, it is not unusual for the radiologist to be the first to diagnose COVID-19 disease in patients especially when the disease is clinically unsuspected. The outbreak of the COVID-19 pandemic may occur in waves and should these waves occur, it will become increasingly important to identify imaging findings suggestive of COVID-19 in a variety of clinical settings,” said Dr. Paul Chang, Vice-Chair, Radiology Informatics at the University of Chicago Medicine. “Aidoc’s ability to detect and triage patients with incidental findings associated with COVID-19 acts as another layer of protection as the disease may continue to circulate in the months to come.”

Nearly 30% of Ransomware Attacks Occur on the Weekend

In studies published by universities of BrusselsChicago, and Brescia, as well as a report from Maimonides Medical Center in New York, 8-10% of patients undergoing CT scans for other conditions were discovered by radiologists to have COVID-19. These patients, who were undergoing oncology screenings or being screened for abdominal pain, did not exhibit any COVID-associated respiratory symptoms. Prompt identification of these incidental findings allows the action to be taken sooner with regard to treatment or appropriate isolation.